Squarepoint
CYT

Squarepoint’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Squarepoint’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-67,219
Closed -$204K – 4778
2023
Q4 		$204K Buy
67,219
+16,341
+32% +$49.6K ﹤0.01% 3584
2023
Q3 		$144K Buy
+50,878
New +$140K ﹤0.01% 3498

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Squarepoint's CYT Position: Q1 2024 in Review

Squarepoint sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 67,219 shares — an estimated $204K sold.

Squarepoint first reported a position in CYT in Q3 2023 and held it in 2 quarters. The position peaked at $204K in Q4 2023. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • Squarepoint reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Squarepoint sold 67,219 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $204K.
  • Squarepoint first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
  • Squarepoint's Cyteir Therapeutics, Inc. Common Stock position peaked at $204K in Q4 2023.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Squarepoint's 13F filing for Q1 2024, filed 15 May 2024.